Sequence: Not specified as a single sequence (synthetic guanidinated α-helical polypeptide prepared from PLG-NCA; DP≈113); composition-based polymer.
| Experiment Id | EXP001722 |
|---|---|
| Paper | Self-Assisted Membrane-Penetrating Helical Polypeptides Mediate Anti-Inflammatory RNAi against Myoca |
| Peptide | P-Anth |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 1 µg/mL siRNA (transfection and most in vitro assays); 2 µg/mL siRNA for mechanistic uptake/escape studies |
| Mixing Ratio | Polypeptide/siRNA weight ratio = 15 for main in vitro transfection (and uptake assays) |
| Formulation Format | Helical polypeptide/siRNA polyplexes by simple mixing and incubation |
| Formulation Components | Polypeptide (1 mg/mL) mixed with siRNA (1 mg/mL) at various polymer/siRNA weight ratios; incubate 30 min RT. |
| Size Nm | 100.00 |
| Zeta Mv | 5.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | H9C2 (rat heart myoblast) |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro gene knockdown |
| Output Value | RAGE mRNA knockdown in H9C2 under hypoxic challenge; P-Ben and P-Anth ~70% knockdown (best performers). |
| Output Units | |
| Output Notes | H9C2 transfection: serum-free DMEM 4 h with polyplexes (1 µg/mL siRNA; polypeptide/siRNA w/w=15); then 20 h serum; then 6 h hypoxia (1% O2) before qPCR. |
| Toxicity Notes | MTT: viability decreases with higher w/w; at w/w=15, P-Ben and P-Naph ~85% viability; P-Biph/P-Anth/P-Pyre more toxic. |
| Curation Notes |